Bispecific antibodies emerge as powerful new cancer-fighting tool

Bispecific antibodies, engineered to bind two molecular targets at once, are rapidly entering clinical use in oncology. Their dual-target mechanism delivers a one-two punch against tumour cells. Researchers are now developing even more elaborate versions of these molecules.